SBC on Nasdaq
SBC Medical Group Holdings Inc
American Offices and Clinics of Doctors of Medicine services company. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with LifeMD, Inc., Airsculpt Technologies, Inc. or Concord Medical Services Holdings Ltd, or pick any stock.
- TickerSBC on Nasdaq1
- IndustryServices-Offices & Clinics of Doctors of Medicine1
- HeadquartersIrvine, California1
- Incorporated inDE2
- Business address200 Spectrum Center Dr., Suite 300, Irvine, Ca 926182
- Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2
See how the biggest companies compare on our leaderboards
We were originally incorporated in Delaware on March 11, 2022 under the name “Pono Capital Two, Inc.,” referred to herein as “Pono,” as a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
73.3%Gross margin4
38.9%Operating margin4
29.4%Net margin4
-15.5%Revenue growth, 20254
20.5%Return on equity4
0.17×Debt to equity4
$23.3MFree cash flow4
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Procurement Services brought in 32% of the revenue SBC Medical Group Holdings Inc broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Procurement Services | $54.8M | $56.1M |
| Franchising | $61.0M | $45.9M |
| Management Services | $53.1M | $29.6M |
| Rental Income | $16.1M | $23.0M |
| Other | $20.3M | $18.9M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue25¢$46.3M
- Selling, general and admin32¢$59.8M
- Interest0¢$148.2K
- Income tax16¢$31.0M
- Profit27¢$51.0M
Out of $173.6M in revenue.4
Where each dollar of operating cash went, fiscal 2025
- Capital spending6¢$1.4M
- Share buybacks20¢$5.0M
- Kept or used elsewhere74¢$18.3M
Out of $24.7M of cash from operations.4
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenues, net | $173.6M | $205.4M |
| Gross profit | $127.3M | $156.1M |
| Selling, general and administrative expenses (including selling, general and administrative expenses from related parties of $751,096 and nil for the years ended December 31, 2025 and 2024, respectively) | $59.8M | $57.7M |
| Stock-based compensation | $0 | $13.0M |
| Impairment loss on intangible asset | $0 | $15.1M |
| Total operating expenses | $59.8M | $85.7M |
| Income from operations | $67.5M | $70.3M |
| Interest income | $198.3K | $19.9K |
| Interest expense | -$160.6K | -$28.3K |
| Foreign currency exchange gain, net | $2.0M | $895.7K |
| Other expenses | -$1.3M | -$5.5M |
| Gain on redemption of life insurance policies | $8.7M | $0 |
| Gain on disposal of subsidiary | $0 | $3.8M |
| Total other income | $14.6M | $3.2M |
| Income before income taxes | $82.1M | $73.5M |
| Effective tax rate | $31.0M | $26.8M |
| Net income | $51.0M | $46.7M |
| Less: net income attributable to non-controlling interests | $59.4K | $75.6K |
| Net income attributable to SBC Medical Group Holdings Incorporated | $51.0M | $46.6M |
| Foreign currency translation adjustment | -$2.9M | -$16.6M |
| Total comprehensive income | $48.1M | $30.1M |
| Less: comprehensive income attributable to non-controlling interests | $225.7K | $117.8K |
| Comprehensive income attributable to SBC Medical Group Holdings Incorporated | $47.9M | $30.0M |
| Net income per share attributable to SBC Medical Group Holdings Incorporated - Basic | $0.50 | $0.48 |
| Net income per share attributable to SBC Medical Group Holdings Incorporated - Diluted | $0.50 | $0.48 |
| Weighted average shares outstanding - Basic | 103.0M shares | 96.6M shares |
| Weighted average shares outstanding - Diluted | 103.0M shares | 96.6M shares |
| Cost of revenues | $46.3M | $49.4M |
| Other income | $5.1M | $3.9M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2024-09-30 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $163.8M | $125.0M | ||
| Inventories | $2.8M | $1.5M | ||
| Short-term investments - related parties | $319.2K | $0 | ||
| Finance lease receivables, current - related parties | $12.8M | $6.0M | ||
| Income tax recoverable | $1.2M | $0 | ||
| Customer loans receivable, current | $8.7M | $10.4M | ||
| Prepaid expenses and other current assets | $11.7M | $11.3M | ||
| Total current assets | $231.2M | $184.5M | ||
| Property and equipment, net | $7.5M | $8.8M | ||
| Intangible assets, net | $47.7M | $1.6M | ||
| Equity method investments | $20.3M | $0 | ||
| Goodwill, net | $15.4M | $4.6M | ||
| Finance lease receivables, non-current - related parties | $13.7M | $8.4M | ||
| Operating lease right-of-use assets | $8.4M | $5.3M | ||
| Finance lease right-of-use assets | $450.9K | $0 | ||
| Deferred tax assets | $4.0M | $9.8M | ||
| Customer loans receivable, non-current | $4.8M | $5.0M | ||
| Long-term prepayments | $393.3K | $1.7M | ||
| Other assets | $7.3M | $15.6M | ||
| Total non-current assets | $149.2M | $81.6M | ||
| Total assets | $380.4M | $266.1M | ||
| Bank and other borrowings, current | $9.1M | $96.8K | ||
| Notes payables, current - related parties | $0 | $26.3K | ||
| Income tax payable | $8.8M | $18.7M | ||
| Operating lease liabilities, current | $4.4M | $4.3M | ||
| Finance lease liabilities, current | $132.9K | $0 | ||
| Accrued liabilities and other current liabilities | $11.5M | $8.1M | ||
| Total current liabilities | $61.1M | $61.2M | ||
| Bank and other borrowings, non-current | $33.7M | $6.5M | ||
| Notes payables, non-current - related parties | $0 | $5.3K | ||
| Deferred tax liabilities | $16.4M | $926.0K | ||
| Operating lease liabilities, non-current | $4.1M | $1.2M | ||
| Finance lease liabilities, non- current portion | $116.5K | $0 | ||
| Other liabilities | $1.7M | $1.2M | ||
| Total non-current liabilities | $56.0M | $9.9M | ||
| Total liabilities | $117.1M | $71.1M | ||
| Preferred stock ($0.0001 par value, 20,000,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and 2024) | $0 | $0 | ||
| Common stock ($0.0001 par value, 400,000,000 shares authorized, 103,881,251 and 103,020,816 shares issued, 102,576,943 and 102,750,816 shares outstanding as of December 31, 2025 and 2024, respectively) | $10.4K | $10.3K | ||
| Additional paid in capital | $72.9M | $62.5M | $8.4M | |
| Treasury stock (at cost, 1,304,308 and 270,000 shares as of December 31, 2025 and 2024, respectively) | -$7.7M | -$2.7M | ||
| Retained earnings | $240.4M | $189.5M | ||
| Accumulated other comprehensive loss | -$57.3M | -$54.2M | ||
| Total SBC Medical Group Holdings Incorporated stockholders equity | $248.3M | $195.1M | ||
| Non-controlling interests | $15.0M | -$87.0K | ||
| Total stockholders' equity | $263.3M | $195.0M | $143.8M | |
| Total liabilities and stockholders equity | $380.4M | $266.1M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 20.0M shares | 20.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares oustanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 400.0M shares | 400.0M shares | ||
| Common stock, shares issued | 103.9M shares | 103.0M shares | ||
| Common stock, shares outstanding | 102.6M shares | 102.8M shares | ||
| Treasury stock, common, shares | 1.3M shares | 270.0K shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2024-09-30 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $163.8M | $125.0M | ||
| Inventories | $2.8M | $1.5M | ||
| Short-term investments - related parties | $319.2K | $0 | ||
| Finance lease receivables, current - related parties | $12.8M | $6.0M | ||
| Income tax recoverable | $1.2M | $0 | ||
| Customer loans receivable, current | $8.7M | $10.4M | ||
| Prepaid expenses and other current assets | $11.7M | $11.3M | ||
| Total current assets | $231.2M | $184.5M | ||
| Property and equipment, net | $7.5M | $8.8M | ||
| Intangible assets, net | $47.7M | $1.6M | ||
| Equity method investments | $20.3M | $0 | ||
| Goodwill, net | $15.4M | $4.6M | ||
| Finance lease receivables, non-current - related parties | $13.7M | $8.4M | ||
| Operating lease right-of-use assets | $8.4M | $5.3M | ||
| Finance lease right-of-use assets | $450.9K | $0 | ||
| Deferred tax assets | $4.0M | $9.8M | ||
| Customer loans receivable, non-current | $4.8M | $5.0M | ||
| Long-term prepayments | $393.3K | $1.7M | ||
| Other assets | $7.3M | $15.6M | ||
| Total non-current assets | $149.2M | $81.6M | ||
| Total assets | $380.4M | $266.1M | ||
| Bank and other borrowings, current | $9.1M | $96.8K | ||
| Notes payables, current - related parties | $0 | $26.3K | ||
| Income tax payable | $8.8M | $18.7M | ||
| Operating lease liabilities, current | $4.4M | $4.3M | ||
| Finance lease liabilities, current | $132.9K | $0 | ||
| Accrued liabilities and other current liabilities | $11.5M | $8.1M | ||
| Total current liabilities | $61.1M | $61.2M | ||
| Bank and other borrowings, non-current | $33.7M | $6.5M | ||
| Notes payables, non-current - related parties | $0 | $5.3K | ||
| Deferred tax liabilities | $16.4M | $926.0K | ||
| Operating lease liabilities, non-current | $4.1M | $1.2M | ||
| Finance lease liabilities, non- current portion | $116.5K | $0 | ||
| Other liabilities | $1.7M | $1.2M | ||
| Total non-current liabilities | $56.0M | $9.9M | ||
| Total liabilities | $117.1M | $71.1M | ||
| Preferred stock ($0.0001 par value, 20,000,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and 2024) | $0 | $0 | ||
| Common stock ($0.0001 par value, 400,000,000 shares authorized, 103,881,251 and 103,020,816 shares issued, 102,576,943 and 102,750,816 shares outstanding as of December 31, 2025 and 2024, respectively) | $10.4K | $10.3K | ||
| Additional paid in capital | $72.9M | $62.5M | $8.4M | |
| Treasury stock (at cost, 1,304,308 and 270,000 shares as of December 31, 2025 and 2024, respectively) | -$7.7M | -$2.7M | ||
| Retained earnings | $240.4M | $189.5M | ||
| Accumulated other comprehensive loss | -$57.3M | -$54.2M | ||
| Total SBC Medical Group Holdings Incorporated stockholders equity | $248.3M | $195.1M | ||
| Non-controlling interests | $15.0M | -$87.0K | ||
| Total stockholders' equity | $263.3M | $195.0M | $143.8M | |
| Total liabilities and stockholders equity | $380.4M | $266.1M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 20.0M shares | 20.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares oustanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 400.0M shares | 400.0M shares | ||
| Common stock, shares issued | 103.9M shares | 103.0M shares | ||
| Common stock, shares outstanding | 102.6M shares | 102.8M shares | ||
| Treasury stock, common, shares | 1.3M shares | 270.0K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net income | $51.0M | $46.7M |
| Depreciation and amortization expense | $2.7M | $3.8M |
| Non-cash lease expense | $4.7M | $3.9M |
| Provision for (reversal of) credit losses | $302.9K | -$402.2K |
| Stock-based compensation | $0 | $13.0M |
| Impairment loss on intangible asset | $0 | $15.1M |
| Impairment loss on long-term investments | $133.5K | $529.6K |
| Fair value change of long-term investments | -$247.5K | $2.6M |
| Gain on disposal of subsidiary | $0 | -$3.8M |
| Gain on redemption of life insurance policies | -$8.7M | $0 |
| Loss (gain) on disposal of property and equipment and intangible assets | -$3.2M | $511.9K |
| Gain on previously held equity interest | -$815.3K | $0 |
| Deferred income taxes | $5.3M | -$14.4M |
| Inventories | -$170.2K | $1.1M |
| Finance lease receivables - related parties | -$12.7M | -$6.0M |
| Customer loans receivable | $15.8M | $18.5M |
| Prepaid expenses and other current assets | $332.3K | -$2.3M |
| Long-term prepayments | $318.5K | $1.9M |
| Other assets | -$195.8K | -$1.7M |
| Accounts payable | $2.7M | -$9.6M |
| Accounts payable - related parties | -$8.6K | $682.3K |
| Notes payables - related parties | -$14.3M | -$34.8M |
| Income tax payable | -$11.7M | $11.2M |
| Operating lease liabilities | -$4.9M | -$4.0M |
| Accrued liabilities and other current liabilities | $3.0M | -$12.1M |
| Other liabilities | $11.0K | $40.2K |
| NET CASH PROVIDED BY OPERATING ACTIVITIES | $24.7M | $20.6M |
| Purchase of property and equipment | -$1.4M | -$2.6M |
| Purchase of convertible note | $0 | -$1.7M |
| Prepayments for property and equipment | -$968.8K | -$843.7K |
| Advances to related parties | $0 | -$622.8K |
| Payments made on behalf of related parties | -$1.8M | -$5.6M |
| Purchase of short-term investments-related parties | -$334.2K | $0 |
| Purchase of long-term investments | -$654.1K | -$331.5K |
| Purchase of cryptocurrencies | -$424.2K | $0 |
| Proceeds from disposal of cryptocurrencies | $457.8K | $0 |
| Purchase of equity method investments | -$20.1M | $0 |
| Cash paid for acquisition of subsidiaries, net of cash acquired | -$22.9M | -$4.2M |
| Long-term loans to others | -$14.5K | -$172.4K |
| Repayments from related parties | $1.9M | $6.6M |
| Repayments from others | $83.7K | $176.1K |
| Proceeds from redemption of life insurance policies | $17.7M | $0 |
| Disposal of subsidiaries, net of cash disposed of | $0 | -$832.4K |
| Proceeds from disposal of property and equipment | $7.5M | $0 |
| NET CASH USED IN INVESTING ACTIVITIES | -$21.0M | -$10.1M |
| Borrowings from bank and others | $34.8M | $6.6M |
| Borrowings from related parties | $15.0K | $5.5M |
| Proceeds from reverse recapitalization, net of transaction costs | $0 | $11.7M |
| Proceeds from exercise of stock warrants | $0 | $31.4K |
| Repayments of bank and other borrowings | -$1.4M | -$119.0K |
| Repayments of finance lease liabilities | -$331.4K | $0 |
| Repayments to related parties | -$145.9K | -$739.4K |
| Repurchase of common stock | -$5.0M | $0 |
| Deemed contribution in connection with price modification on disposal of property and equipment | $10.4M | $0 |
| Net cash used in financing activities | $38.3M | $23.0M |
| Effect of exchange rate changes | -$3.3M | -$11.4M |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | $38.7M | $22.0M |
| Cash paid for interest expense | $160.6K | $28.3K |
| Cash paid for income taxes, net | $37.2M | $30.2M |
| Property and equipment transferred from long-term prepayments | $1.5M | $597.6K |
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | $1.3M | $0 |
| Finance lease right-of-use assets obtained in exchange for finance lease liabilities | $612.5K | $0 |
| Remeasurement of operating lease liabilities and right-of-use assets due to lease modifications | $5.3M | $2.9M |
| Payables to related parties in connection with loan services provided | $14.2M | $20.5M |
| Issuance of common stock as incentive shares | $86 | $0 |
| Issuance of common stock from conversion of convertible note | $0 | $2.7M |
| Deemed contribution in connection with disposal of subsidiaries | $0 | $1.5M |
No quarter-by-quarter statement was filed.
Leadership
Who has led SBC Medical Group Holdings Inc, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2025
- Chief executive officerYoshiyuki Aikawa Sep 17, 2024 to now10
- Chief executive officerDarryl Nakamoto Aug 10, 2022 to Aug 10, 202211
- ChairYoshiyuki Aikawa Sep 17, 2024 to now10
- Chief financial officerRyoji Murata Sep 17, 2024 to Sep 17, 202412
- Chief financial officerOrman Allison Van Aug 4, 2022 to Aug 4, 202213
- Chief operating officerYuya Yoshida Sep 17, 2024 to Sep 17, 202414
Board members and other officers (9)
- Chief Strategy OfficerMiki Yamazaki Apr 18, 2025 to now15
- CSO and SecretaryAkira Komatsu Sep 17, 2024 to Sep 17, 202416
- Board memberFumitoshi Fujiwara Sep 17, 2024 to Sep 17, 202417
- Board memberKen Edahiro Sep 17, 2024 to Sep 17, 202418
- Board memberYuya Yoshida Sep 17, 2024 to Sep 17, 202414
- Board memberDustin M. Shindo Aug 4, 2022 to Mar 8, 202319
- Board memberKotaro Chiba Aug 4, 2022 to Aug 4, 202220
- Board memberMike K. Sayama Aug 4, 2022 to Sep 30, 202421
- Board memberTrisha Nomura Aug 4, 2022 to Aug 4, 202222
Former names
- Pono Capital Two, Inc.Jun 14, 2022 to Aug 29, 20242
Timeline
Filings
232 filings to the SEC since October 2021: 7 annual reports, 13 quarterly reports, 46 major events, 54 insider forms, 25 large holders, 87 other. The latest 20:
- Aug 13, 202610-Q EDGAR
- Aug 13, 20268-K EDGAR
- Jul 14, 20268-K EDGAR
- May 28, 2026ARS EDGAR
- May 28, 2026DEFA14A EDGAR
- May 28, 2026DEF 14A EDGAR
- May 20, 20268-K EDGAR
- May 15, 2026PRE 14A EDGAR
- May 14, 202610-Q EDGAR
- May 14, 20268-K EDGAR
- Apr 30, 202610-K/A EDGAR
- Apr 29, 20264 EDGAR
- Apr 23, 20264 EDGAR
- Apr 23, 20268-K EDGAR
- Apr 21, 2026SCHEDULE 13D/A EDGAR
- Apr 20, 2026424B7 EDGAR
- Apr 17, 2026424B7 EDGAR
- Mar 27, 20268-K EDGAR
- Mar 27, 202610-K EDGAR
- Mar 13, 2026SCHEDULE 13G EDGAR
The 232 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
61 open-market trades by officers, directors and large owners since October 2021: 54 buys and 7 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Apr 28, 2026 | Aikawa YoshiyukiChairman and CEO | Sale | 465,000 | $3.02 | $1.4M | Form 4 |
| Apr 21, 2026 | Aikawa YoshiyukiChairman and CEO | Sale | 3,100,000 | $3.02 | $9.4M | Form 4 |
| Mar 6, 2026 | Aikawa YoshiyukiChairman and CEO | Sale | 4,422,900 | $2.12 | $9.4M | Form 4 |
| Sep 19, 2024 | ZUU Funders Co. Ltd.10% owner | Sale | 6,196 | $7.34 | $45.5K | Form 4 |
| Aug 22, 2024 | ZUU Target Fund for SBC Medical Group HD Investment Partnership10% owner | Buy | 8,399 | $10.51 | $88.3K | Form 4 |
| Aug 21, 2024 | ZUU Target Fund for SBC Medical Group HD Investment Partnership10% owner | Sale | 4,755 | $11.38 | $54.1K | Form 4 |
| Aug 20, 2024 | Tomita Kazumasa10% owner | Sale | 5,000 | $11.72 | $58.6K | Form 4 |
| Aug 19, 2024 | Tomita Kazumasa10% owner | Sale | 70,000 | $11.45 | $801.5K | Form 4 |
| Aug 1, 2024 | ZUU Funders Co. Ltd.10% owner | Buy | 2,487 | $12.82 | $31.9K | Form 4 |
| Jul 31, 2024 | ZUU Funders Co. Ltd.10% owner | Buy | 12 | $12.50 | $150 | Form 4 |
| Jul 24, 2024 | Tomita Kazumasa10% owner | Buy | 15,509 | $13.00 | $201.6K | Form 4 |
| Jul 19, 2024 | ZUU Co. Ltd.10% owner | Buy | 2 | $13.00 | $26 | Form 4 |
| Jul 17, 2024 | ZUU Co. Ltd.10% owner | Buy | 5,404 | $13.00 | $70.3K | Form 4 |
| Jul 15, 2024 | Tomita Kazumasa10% owner | Buy | 4,342 | $13.00 | $56.4K | Form 4 |
| Jul 12, 2024 | Tomita Kazumasa10% owner | Buy | 203 | $13.00 | $2.6K | Form 4 |
| Jul 11, 2024 | ZUU Co. Ltd.10% owner | Buy | 6,297 | $13.00 | $81.9K | Form 4 |
| Jul 10, 2024 | ZUU Co. Ltd.10% owner | Buy | 12 | $13.00 | $156 | Form 4 |
| Jul 9, 2024 | ZUU Co. Ltd.10% owner | Buy | 5 | $13.00 | $65 | Form 4 |
| Jul 2, 2024 | ZUU Co. Ltd.10% owner | Buy | 30 | $13.00 | $390 | Form 4 |
| Jun 27, 2024 | Tomita Kazumasa10% owner | Buy | 2 | $13.00 | $26 | Form 4 |
All 61 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Yoshiyuki AikawaSCHEDULE 13D/A, 4 filings Sep 23, 2024 to Apr 21, 202623
- Aikawa Equity Management Co., Ltd.SCHEDULE 13G, 1 filing Mar 13, 202624
- ZUU Co. Ltd.SC 13D/A, 8 filings Feb 6, 2024 to Oct 1, 202425
- Radcliffe Capital Management, L.P.SC 13G/A, 2 filings May 10, 2023 to Jun 28, 202426
- WOLVERINE ASSET MANAGEMENT LLCSC 13G/A, 2 filings Feb 8, 2024 to Mar 1, 202427
- Shaolin Capital Management LLCSC 13G/A, 2 filings Feb 14, 2023 to Feb 22, 202428
- Mehana Capital LLCSC 13G, 1 filing Feb 14, 202429
- Polar Asset Management Partners Inc.SC 13G/A, 3 filings Feb 10, 2023 to Feb 12, 202430
- Space Summit Capital LLCSC 13G/A, 2 filings Aug 8, 2022 to Feb 8, 202331
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 57. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARAkira Komatsu, CSO and Secretary
- 17SEC EDGARFumitoshi Fujiwara, Board member
- 18SEC EDGARKen Edahiro, Board member
- 19SEC EDGARDustin M. Shindo, Board member
- 20SEC EDGARKotaro Chiba, Board member
- 21SEC EDGARMike K. Sayama, Board member
- 22SEC EDGARTrisha Nomura, Board member
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31